Analysts Set Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Price Target at $105.95

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has been given an average recommendation of “Hold” by the twenty-three ratings firms that are covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $105.9524.

A number of equities analysts recently issued reports on ZBH shares. William Blair assumed coverage on Zimmer Biomet in a report on Friday, February 20th. They issued a “market perform” rating for the company. UBS Group reissued a “sell” rating and set a $89.00 price objective on shares of Zimmer Biomet in a report on Wednesday, February 11th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Tuesday, February 10th. TD Cowen upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Monday, January 26th. Finally, The Goldman Sachs Group cut shares of Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price target for the company. in a research report on Friday, January 9th.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $92.57 on Friday. Zimmer Biomet has a 12 month low of $84.59 and a 12 month high of $108.29. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.98 and a quick ratio of 1.10. The firm has a market capitalization of $17.92 billion, a PE ratio of 26.15, a price-to-earnings-growth ratio of 1.87 and a beta of 0.61. The business’s fifty day moving average price is $93.52 and its 200 day moving average price is $92.98.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The business had revenue of $2.24 billion during the quarter, compared to analysts’ expectations of $2.22 billion. During the same period in the prior year, the firm posted $2.31 EPS. The business’s quarterly revenue was up 10.9% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, sell-side analysts anticipate that Zimmer Biomet will post 8.39 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s payout ratio is presently 27.12%.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of Zimmer Biomet stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $94.66, for a total transaction of $250,849.00. Following the transaction, the senior vice president owned 10,224 shares of the company’s stock, valued at $967,803.84. The trade was a 20.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 1.28% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Zimmer Biomet

A number of hedge funds have recently modified their holdings of the business. Dodge & Cox boosted its stake in Zimmer Biomet by 1.3% during the 4th quarter. Dodge & Cox now owns 23,506,849 shares of the medical equipment provider’s stock worth $2,113,736,000 after purchasing an additional 290,676 shares during the period. Vanguard Group Inc. increased its stake in Zimmer Biomet by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 23,483,741 shares of the medical equipment provider’s stock valued at $2,111,658,000 after purchasing an additional 192,517 shares during the period. State Street Corp raised its holdings in shares of Zimmer Biomet by 2.3% in the fourth quarter. State Street Corp now owns 8,826,974 shares of the medical equipment provider’s stock valued at $795,814,000 after buying an additional 195,214 shares during the last quarter. Capital International Investors boosted its stake in shares of Zimmer Biomet by 11.5% during the third quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock worth $743,749,000 after buying an additional 778,467 shares during the period. Finally, Franklin Resources Inc. boosted its stake in shares of Zimmer Biomet by 43.2% during the fourth quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock worth $601,204,000 after buying an additional 2,017,857 shares during the period. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.